Purification and characterization of nuclear alkaline phospholipase A2 in rat ascites hepatoma cells

The alkaline phospholipase A2 (PLA2) was purified from nuclei of rat ascites hepatoma cells (AH7974) by column chromatography with a Sephacryl S-300 column and an immunoadsorbent using anti-group II PLA2 monoclonal antibody. From these two columns, the alkaline PLA2 was eluted in parallel with a 17-kDa protein which is reactive to another anti-group II PLA2 polyclonal antibody. Approximately 80% of nuclear PLA2 was inhibited by this antibody. The alkaline PLA2 was found in association with the chromatin fraction among subnuclear fractions. By an immunocytochemical staining, the nuclei of AH7974 were stained more strongly than other parts of cells with anti-group II PLA2 antiserum.

Function of type II phospholipase A2 in dopamine secretion by rat neuronal PC12 cells

When rat pheochromocytoma PC12 cells, which had differentiated into neuron-like cells following culture with nerve growth factor, were activated with glutamate, approximately 40% of their type II phospholipase A2 (PLA2) was released into the extracellular medium. Glutamate-stimulated secretion of dopamine from PC12 cells was suppressed by type II PLA2 inhibitors. Exogenous type II PLA2 added alone directly elicited release of dopamine from PC12 cells. Thus released type II PLA2 may be involved in the regulation of neurotransmitter exocytosis by PC12 cells.

Release of secretory phospholipase A2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion

Here we show that secretory phospholipase A2 (sPLA2) that is immunochemically indistinguishable from type II sPLA2 is (i) stored in neuroendocrine cells, (ii) released in response to neurotransmitters or depolarization, and (iii) involved in the regulation of catecholamine secretion by these cells. Rat brain synaptic vesicle fractions contained PLA2 activity, which was neutralized completely by an antibody raised against rat type II sPLA2. sPLA2 immunoreactive with anti-(type II sPLA2) antibody was released from synaptosomes in response to depolarization evoked by a high concentration of potassium in the presence of Ca2+. Rat pheochromocytoma PC12 cells, which differentiated into adherent cells similar to sympathetic neurons in response to nerve growth factor, were used for the detailed analysis of the dynamics and function of sPLA2 in neuronal cells. Antibody against rat type II sPLA2 precipitated approximately 80% of the PLA2 activity in PC12 cell lysates. Transcript for type II sPLA2 was detected in PC12 cells by reverse transcriptase-PCR. When neuronally differentiated PC12 cells were stimulated with carbamylcholine or potassium, sPLA2 was released into the medium and reached a maximal approximately 40% release by 15 min. Inhibitors specific to type II sPLA2 suppressed catecholamine secretion by PC12 cells which had been activated by carbamylcholine. Furthermore, treatment of PC12 cells with exogenous type II sPLA2 alone elicited catecholamine secretion. These observations indicate that sPLA2 released from neuronal cells may regulate the degranulation process leading to release of neurotransmitters and are compatible with our earlier finding that this enzyme is involved in the degranulation of rat mast cells.

p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma

To examine the expression of p53 protein and gene alterations in oral epithelial lesions including epithelial dysplasias and primary squamous cell carcinomas, immunohistochemical and temperature gradient gel electrophoresis (TGGE) methods were applied to formalin-fixed and paraffin-embedded tissues. Morphologically normal mucosal epithelium stained negatively for p53 protein. Three out of 11 (27.3 per cent) epithelial dysplasias and 19 out of 57 (33.3 per cent) primary squamous cell carcinomas stained positively for p53 protein. Although more than half of the cases were positive for p53 protein in stage I, the positive cancer cases were found at other stages with variable frequency. Immunoreactive products were localized in the nucleus, especially in the basal and suprabasal layers. The analysis by TGGE revealed gene alterations in exons 5-8 in 3 out of 3 epithelial dysplasias and 17 out of 19 (89.5 per cent) primary squamous cell carcinomas which were immunohistochemically positive for p53 protein. These results suggest that p53 gene mutation may be involved in carcinogenesis in the oral squamous epithelium even in the early stage of the dysplasia-carcinoma sequence.

Clinical assessment of the pumping technique in treating TMJ arthrosis with closed lock

The treatment of closed jaw locking due to temporomandibular joint (TMJ) arthrosis is described. Conventional mandibular manipulation of the lower and/or upper joint compartments was performed using hydraulic pressure from an imaging X-ray medium. The procedure was used in 40 patients with closed locking (5 acute and 35 chronic). The results of the treatment are evaluated and factors affecting the results are examined. In four of the five patients with acute closed locking, the lock was successfully released after use of the pumping technique on the lower joint compartment. In patients with chronic locking, an average improvement of 6.6 mm in the degree of interincisal opening was observed within 3-4 days of treatment with the pumping technique. In 13 of these patients, satisfactory opening (at least 40 mm) was achieved immediately. All the patients underwent further forward and contralateral manipulation to assist mouth opening, and after a period of 2-3 months 16 patients showed a further average improvement of 5.4 mm in interincisal opening.

Lysophosphatidylserine enhances exogenous type II phospholipase A2-induced activation of rat serosal mast cells

We have previously shown that exogenous type II phospholipase A2 (PLA2) alone elicits degranulation of mast cells, including rat serosal mast cells (SMC) and mouse bone marrow-derived mast cells (BMMC). Here we report that lysophosphatidylserine (lysoPS), a co-factor for activation of rodent SMC in response to some tyrosine kinase-coupled agonists, enhanced type II PLA2-elicited histamine release from rat SMC. In contrast, mouse BMMC was insensitive to lysoPS. Our findings demonstrate a novel route for activation of SMC in that type II PLA2 can act as a direct activator of SMC with enhancement by lysoPS, which is generated from membrane phosphatidylserine possibly by the action of the same enzyme.

IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts

Activated T cells secrete the cytokine IL-13, which regulates inflammatory and immune responses. To explore the role of IL-13 in bone metabolism, we examined the effects of the cytokine on bone resorption and PG synthesis in osteoblasts. IL-13 suppressed the bone-resorbing activity stimulated by IL-1 alpha, which was determined by the release of 45Ca from prelabeled mouse long bones. Histologic examinations revealed that IL-1 alpha markedly stimulated bone resorption with increased osteoclast recruitment, and that the simultaneous addition of IL-13 considerably inhibited it. The gamma-chain of IL-2 receptors may be functionally involved in the signal transduction of not only IL-2, but also IL-4, IL-7, and IL-13. Of these cytokines, IL-4 similarly suppressed IL-1 alpha-induced bone resorption, but IL-2 and IL-7 did not. Both IL-13 and IL-4 inhibited PGE2 production stimulated by IL-1 alpha in long bone cultures. Suppression of IL-1 alpha-induced bone resorption by IL-13 and IL-4 was recovered by adding exogenous PGE2 to the long bone cultures. Neither IL-4 nor IL-13 further inhibited IL-1 alpha-induced bone resorption in the presence of indomethacin. To examine the effects of IL-13 on PG synthesis, we measured the mRNA levels of cytosolic phospholipase A2 (cPLA2), constitutively expressed cyclooxygenase (COX-1) and inducible COX (COX-2) in mouse osteoblast-like cells. IL-1 alpha markedly stimulated the mRNA expression of COX-2, but not that of COX-1. Both IL-13 and IL-4 dose-dependently suppressed the IL-1 alpha-induced stimulation of both COX-2 mRNA expression and PGE2 synthesis. A small increase (1.7-fold) in cPLA2 mRNA levels was detected in the cultures with IL-1 alpha, but the expression was not affected by IL-13 or IL-4. These results indicated that IL-13 and IL-4 inhibit bone resorption by suppressing COX-2-dependent PG synthesis in osteoblasts.

IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts

Activated T cells secrete the cytokine IL-13, which regulates inflammatory and immune responses. To explore the role of IL-13 in bone metabolism, we examined the effects of the cytokine on bone resorption and PG synthesis in osteoblasts. IL-13 suppressed the bone-resorbing activity stimulated by IL-1 alpha, which was determined by the release of 45Ca from prelabeled mouse long bones. Histologic examinations revealed that IL-1 alpha markedly stimulated bone resorption with increased osteoclast recruitment, and that the simultaneous addition of IL-13 considerably inhibited it. The gamma-chain of IL-2 receptors may be functionally involved in the signal transduction of not only IL-2, but also IL-4, IL-7, and IL-13. Of these cytokines, IL-4 similarly suppressed IL-1 alpha-induced bone resorption, but IL-2 and IL-7 did not. Both IL-13 and IL-4 inhibited PGE2 production stimulated by IL-1 alpha in long bone cultures. Suppression of IL-1 alpha-induced bone resorption by IL-13 and IL-4 was recovered by adding exogenous PGE2 to the long bone cultures. Neither IL-4 nor IL-13 further inhibited IL-1 alpha-induced bone resorption in the presence of indomethacin. To examine the effects of IL-13 on PG synthesis, we measured the mRNA levels of cytosolic phospholipase A2 (cPLA2), constitutively expressed cyclooxygenase (COX-1) and inducible COX (COX-2) in mouse osteoblast-like cells. IL-1 alpha markedly stimulated the mRNA expression of COX-2, but not that of COX-1. Both IL-13 and IL-4 dose-dependently suppressed the IL-1 alpha-induced stimulation of both COX-2 mRNA expression and PGE2 synthesis. A small increase (1.7-fold) in cPLA2 mRNA levels was detected in the cultures with IL-1 alpha, but the expression was not affected by IL-13 or IL-4. These results indicated that IL-13 and IL-4 inhibit bone resorption by suppressing COX-2-dependent PG synthesis in osteoblasts.

Exogenous type-II phospholipase A2 stimulates prostaglandin synthesis in rat liver-derived BRL-3A cells in the presence of tumor necrosis factor alpha

The effect of extracellular type-II phospholipase A2 (PLA2) on prostaglandin (PG) synthesis has been studied using rat liver-derived BRL-3A cells. The addition of type-II PLA2 to the medium of BRL-3A cells resulted in a marked decrease in the enzymatic activity in the medium. An immunochemical study involving an anti-(type-II PLA2) antibody revealed that a significant amount of PLA2 was attached to the surface of type-II PLA2-treated BRL-3A cells. Heparin inhibited the binding of PLA2 almost completely. Only modest release of PGE2 over the control value was observed when cells were treated with PLA2 alone or tumor necrosis factor alpha (TNF alpha) alone, whereas PGE2 production as well as arachidonic acid release from phospholipids was augmented more than additively in the presence of both type-II PLA2 and TNF alpha. Furthermore, pretreatment of cells with type-II PLA2 followed by subsequent stimulation by TNF alpha caused an appreciable increase in PGE2 production. Thus, type-II PLA2 bound to cell-surface heparin-like molecules may exert its activity and participate in eicosanoid generation only in the presence of TNF alpha.

Activation of phospholipase A2 and acylation of lysophospholipids: the major regulators for platelet activating factor production in rat neutrophils

Rat inflammatory neutrophils induced arachidonic acid release and platelet-activating factor (PAF) production in response to opsonized zymosan (OPZ) dose-dependently. Phospholipase A2 activity also increased dose-dependently, paralleling the increases in arachidonic acid and PAF. The time courses of the activities of phospholipase A2 and acetyltransferase, and the amounts of free arachidonic acid, lyso-PAF, and PAF demonstrated that activation of the enzymes in the remodeling pathway could be required for PAF production in rat neutrophils, which agrees with the documented fact for macrophages. Phospholipase A2 could be a rate-limiting enzyme for PAF production, since an increased lyso-PAF amount or addition of exogenous lyso-PAF reflected the increase in PAF formation in the cells. This phospholipase A2 activity in rat neutrophils could be attributed to cytosolic type phospholipase A2, because the activity was mostly suppressed by a specific antibody to cytosolic phospholipase A2. As previously reported, pretreatment of neutrophils with the acyl-CoA synthetase inhibitor, triacsin C, or the acyltransferase inhibitor, merthiolate, enhanced PAF production as well as arachidonic acid release by the cells in response to OPZ. Triacsin C inhibited arachidonoyl-CoA production and merthiolate suppressed the transacylation of lyso-PAF to 1-alkyl-2-arachidonoyl-GPC. These results suggest that these inhibitors of acylation of lyso-PAF caused accumulation of lyso-PAF, which resulted in enhancement of PAF production when phospholipase A2 and acetyltransferase were activated by OPZ. Thus the activation of cytosolic phospholipase A2 and the acylation of lyso-PAF by such as arachidonic acid could be regulating factors for PAF production in stimulated rat neutrophils.

Detection and purification of two 14 kDa phospholipase A2 isoforms in rat kidney: their role in eicosanoid synthesis

Phospholipase A2 (PLA2) activity in the soluble fraction of rat kidney yielded three peaks on DEAE cellulose column chromatography. From these three, we purified two PLA2 isoforms to near-homogeneity. Both had a molecular weight of approx. 14,000 on SDS-PAGE, and immunochemical and enzymological studies indicated that one is a 14 kDa type I PLA2 and the other a 14 kDa type II PLA2. RNA blot analysis confirmed that rat kidney contains both types of PLA2 and that administration of lipopolysaccharides and mercury chloride into rats increased type II PLA2 mRNA levels in kidney. When cultured rat mesangial cells were incubated with purified type I or type II PLA2 in combination with the calcium ionophore A23187 at suboptimal condition, augmentation of prostaglandin E2 production was observed. Type I and type II forms of PLA2 may play a role in arachidonate metabolism in rat kidney.

Phospholipid degradation in rat calcium ionophore-activated platelets is catalyzed mainly by two discrete secretory phospholipase As

An "A1 type" phospholipase activity with serine-phospholipid preference was released by rat activated platelets. It was distinct from the secretory type II phospholipase A2 [Horigome, K., Hayakawa, M., Inoue, K., and Nojima, S. (1987) J. Biochem. 101, 625-631] and co-purified with the secretory lysophosphatidylserine-selective lysophospholipase activity [Higashi, S., Kobayashi, T., Kudo, I., and Inoue, K. (1988) J. Biochem. 103, 442-447]. Several lines of evidence indicated that a single protein was responsible for the phospholipase A1 and lysophospholipase activities. Marked accumulation of lysophospholipids was observed in rat calcium ionophore-activated washed platelets and both phospholipase A1/lysophospholipase and type II phospholipase A2 were shown to contribute to this phospholipid degradation. A selective inhibitor of type II phospholipase A2 reduced the phospholipid degradation and enhanced the clotting time and prothrombinase activity. These results indicate that secretory platelet phospholipases may play a role in regulation of blood clotting.

A case of osteoporosis with bilateral defects in the mandibular processes

We carried out a detailed total body examination of a 62-year-old woman with osteoporosis who had bilateral defects in the mandibular processes. It was inferred that the defects in both articular heads were caused by resorption of small bone fragments following fracture. The quantity of bone salt was determined by microdensitometry, and a diagnosis of osteoporosis was then established. An improved bite was obtained by treatment consisting of tooth extraction and the preparation of partial dentures.

Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist

Various purified lipoxygenases were incubated with [14C]arachidonylethanolamide which is an endogenous ligand for cannabinoid receptors. When radioactive products were analyzed by thin-layer chromatography, porcine leukocyte 12-lipoxygenase and rabbit reticulocyte and soybean 15-lipoxygenases produced polar compounds at about the same reaction rates as that of oxygenation of free arachidonic acid. In contrast, the reaction of human platelet 12-lipoxygenase proceeded at a much lower rate, and porcine leukocyte 5-lipoxygenase was totally inactive. The result indicated that the lipoxygenases, which had been shown previously to be capable of oxygenating esterified polyunsaturated fatty acids, were also active with the arachidonylethanolamide. High-performance liquid chromatography, ultraviolet and mass spectrometry and nuclear magnetic resonance spectroscopy identified the major product by leukocyte 12-lipoxygenase as 12-hydroperoxy-5,8,10,14-eicosatetraenoylethanolamide and that by 15-lipoxygenases as 15-hydroperoxy-5,8,11,13-eicosatetraenoylethanolamide. The 15-hydroxy derivative inhibited electrically-evoked contraction of mouse vas deferens with an IC50 of 0.63 microM as well as arachidonylethanolamide (0.17 microM), but the 12-hydroxy derivative was much less effective.

Suppressive effects of the anti-allergic drugs, tranilast and azelastine, on the lysophosphatidylserine-dependent activation of rat mast cells

Anti-allergic drugs, tranilast and azelastine, were examined for their effects on lysophosphatidylserine (lysoPS)-dependent histamine release from rat mast cells. Although both compounds suppressed the histamine release in a dose-dependent manner, the inhibition was affected by lysoPS concentration differently. In the presence of an increasing concentration of lysoPS, the suppressive effect of tranilast decreased. The inhibition by azelastine, however, was independent of the concentration of lysoPS. The findings suggest that these two drugs inhibit lysoPS-depedent histamine release through essentially different routes.

Dual regulation of cytosolic phospholipase A2 in mast cells after cross-linking of FC epsilon-receptor

We have reported previously that cultured mast cells (MC) express three discrete phospholipases A2 (PLA2s), one of which corresponds to arachidonoyl-preferential cytosolic PLA2 (cPLA2). In the present study, we investigated the possible role of cPLA2 in eicosanoid synthesis by activating mouse bone marrow-derived mast cells (BMMC) through cross-linking of the high affinity IgE receptor (Fc epsilon RI) with a specific Ag. BMMC released arachidonic acid within 2 min after Fc epsilon RI cross-linking. A rapid, transient phosphorylation of cPLA2 was observed after Fc epsilon RI cross-linking, reaching the maximum within 2 min, and accompanied by an increase of cPLA2 activity in the cell lysate. Exposure of BMMC to the IgE-Ag for longer periods resulted in a time-dependent increase of the cPLA2 protein. The increase was detected within 10 h after stimulation and reached the maximum within 30 h. Dexamethasone inhibited the Ag-stimulated cPLA2 induction significantly. cPLA2 activity in cells stimulated for 24 h was increased significantly, and suppressed in cells treated with dexamethasone. When the cells were exposed to IgE-Ag for 36 h and then challenged with a secondary agonist, thrombin, arachidonate release was augmented significantly in comparison with cells without the Ag pretreatment. Thus, cPLA2 activation in BMMC by short term exposure to the Ag might be regulated by post-Fc epsilon RI modification (phosphorylation) of pre-existing enzyme, whereas that observed after long term exposure might be explained by the increase in cPLA2 protein.

Dual regulation of cytosolic phospholipase A2 in mast cells after cross-linking of FC epsilon-receptor

We have reported previously that cultured mast cells (MC) express three discrete phospholipases A2 (PLA2s), one of which corresponds to arachidonoyl-preferential cytosolic PLA2 (cPLA2). In the present study, we investigated the possible role of cPLA2 in eicosanoid synthesis by activating mouse bone marrow-derived mast cells (BMMC) through cross-linking of the high affinity IgE receptor (Fc epsilon RI) with a specific Ag. BMMC released arachidonic acid within 2 min after Fc epsilon RI cross-linking. A rapid, transient phosphorylation of cPLA2 was observed after Fc epsilon RI cross-linking, reaching the maximum within 2 min, and accompanied by an increase of cPLA2 activity in the cell lysate. Exposure of BMMC to the IgE-Ag for longer periods resulted in a time-dependent increase of the cPLA2 protein. The increase was detected within 10 h after stimulation and reached the maximum within 30 h. Dexamethasone inhibited the Ag-stimulated cPLA2 induction significantly. cPLA2 activity in cells stimulated for 24 h was increased significantly, and suppressed in cells treated with dexamethasone. When the cells were exposed to IgE-Ag for 36 h and then challenged with a secondary agonist, thrombin, arachidonate release was augmented significantly in comparison with cells without the Ag pretreatment. Thus, cPLA2 activation in BMMC by short term exposure to the Ag might be regulated by post-Fc epsilon RI modification (phosphorylation) of pre-existing enzyme, whereas that observed after long term exposure might be explained by the increase in cPLA2 protein.

A possible role for extracellular bicarbonate in U-46619-induced rat platelet aggregation

U-46619, a thromboxane A2 agonist, has been believed not to induce aggregation of rat platelets. However, we have found that U-46619 evoked rat platelet aggregation when the cells were suspended in HCO3-containing medium, whereas it was inactive in medium lacking HCO3-. 4,4'-Diisothiocyanostilbene-2,2'-disulfonate (DIDS), selective inhibitor of the HCO3/Cl- exchanger, inhibited the aggregation of rat platelets induced by U-46619 as well as by collagen and ADP. Thrombin-induced aggregation was also inhibited by DIDS, although to a much lesser extent. Several inhibitors of anion transporters, such as phloretin, pyridoxal phosphate and ethacrynic acid, suppressed U-46619-induced aggregation. These observations indicate that HCO3-influx via an anion exchanger may be involved in the signal transduction pathway of U-46619 in rat platelets.